TL;DR
Researchers have used fragment-based drug discovery (FBDD) to identify potential new drug targets within the L-arginine biosynthesis pathway of Mycobacterium tuberculosis (Mtb). They discovered novel binding sites and initial inhibitors for four key enzymes (ArgB, ArgC, ArgD, and ArgF), with some fragments showing promising activity against Mtb growth.
What Problem Does This Paper Address?
Tuberculosis (TB) remains a major global health threat, exacerbated by the rise of drug-resistant strains. While the L-arginine biosynthesis pathway in Mtb is known to be essential for its survival, only one enzyme (ArgJ) has been explored for drug development. This paper aims to assess the "ligandability" of four other enzymes in this pathway (ArgB, ArgC, ArgD, and ArgF) as potential targets for new anti-TB drugs. The rationale is that targeting essential metabolic pathways, especially those where Mtb is "autarkic" (meaning it relies on its own synthesis rather than scavenging from the host), could lead to effective treatments.
Methods
The study employed a Fragment-Based Drug Discovery (FBDD) approach. This involved:
- Differential Scanning Fluorimetry (DSF): A library of 960 small molecules (fragments, ~150-300 Da) was screened against the four target enzymes. DSF measures changes in protein melting temperature upon fragment binding, indicating interaction.
- Biophysical and Biochemical Validation: Promising fragment "hits" from DSF were further validated using:
- Surface Plasmon Resonance (SPR): To confirm binding and measure kinetics.
- Ligand-Observed NMR: To study fragment binding and potential displacement of natural ligands.
- Isothermal Titration Calorimetry (ITC): To quantify binding affinity (K<sub>a</sub>).
- Enzymatic Assays: To assess the inhibitory effect of fragments on enzyme activity.
- X-ray Crystallography: Crystal structures of the enzymes, both apo (unbound) and in complex with fragments or natural ligands, were determined. This provided crucial structural information about binding sites and interactions.
- M. tuberculosis Growth Inhibition Assays: The most promising inhibitors were tested for their ability to inhibit the growth of Mtb strains, both in the presence and absence of arginine, to confirm on-target activity.
Datasets
Not explicitly discussed as distinct datasets in the paper. The primary "dataset" used was an in-house library of 960 small molecule fragments. Protein structures were obtained from the Protein Data Bank (PDB) for initial phasing during crystallography.
Key Insights and Ideas
- Novel Allosteric Site in ArgB: The most striking finding is the discovery of a new, hydrophobic allosteric binding site on ArgB, located at the interface between two protein subunits. This site is distinct from the active site and the natural ligand (L-arginine) binding site.
- Fragment Binding to Interfacial Sites: For ArgB and ArgF, fragments were found to bind to interfacial sites between protein subunits. This suggests that targeting these interfaces could be a viable strategy for developing inhibitors.
- ArgB Fragments Show On-Target Activity: Two ArgB inhibitors (NMR711 and NMR446) not only inhibited Mtb growth but also showed specific inhibition of arginine biosynthesis, becoming inactive when arginine was supplied. This strongly suggests they are acting on the intended target.
- Divergent Binding Strategies for ArgC: ArgC showed potential for inhibition via two distinct pockets: the substrate-binding site and the cofactor (NADP(H))-binding site, offering multiple avenues for drug design.
- ArgF's Interfacial Site as a Drug Target: While ArgF's active site is conserved with human orthologs, its interfacial binding site shows differences, making it a potentially selective target for Mtb.
Key Results
- Fragment Hits Identified: DSF screening yielded numerous hits for all four enzymes.
- Structural Insights: Crystal structures were obtained for apo-enzymes and enzyme-fragment complexes, revealing binding modes and sites.
- ArgB: 13 fragment structures solved, revealing a novel allosteric site.
- ArgC: 4 fragment structures solved, showing binding to substrate and cofactor sites.
- ArgD: 2 fragment structures solved, binding near the active site.
- ArgF: 8 fragment structures solved, binding to an interfacial site.
- Inhibitory Activity:
- ArgB: Fragments NMR711 and NMR446 showed IC<sub>50</sub> values of 366 µM and 707 µM, respectively, and inhibited Mtb growth.
- ArgC: Fragments showed moderate inhibition (e.g., 45% for NMR322 at 2 mM).
- ArgD: Fragments showed weak inhibition (<31% at 4 mM).
- ArgF: Fragments showed weaker binding affinities (K<sub>a</sub> > 100 µM).
- Mtb Growth Inhibition: NMR711 and NMR446 demonstrated significant inhibition of Mtb growth, with specificity for arginine biosynthesis confirmed by arginine supplementation.
Limitations and Future Work
- ArgB Allosteric Site: The highly hydrophobic nature of the ArgB interfacial site presents a challenge for developing high-affinity inhibitors due to limited opportunities for polar interactions. The lack of significant conformational changes observed in crystal structures also makes rational design difficult.
- ArgD Selectivity: ArgD has human orthologs with significant sequence identity, making selective inhibition of the Mtb enzyme more challenging.
- Fragment Potency: While fragments are good starting points, their intrinsic potency is often low. Further elaboration and optimization are required to develop potent drug candidates.
- Future Work: The authors suggest that ArgC and ArgF are particularly promising candidates for future drug discovery programs due to the identified binding sites and potential for selectivity. Further work will focus on elaborating the identified fragments into more potent inhibitors and exploring the therapeutic potential of targeting these enzymes.
Summary updated